ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Synthesis and characterization of NiTiO₃-L-ornithine nanoparticles and their antibacterial, antifungal, antioxidant activities, and zebrafish biocompatibility.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of antimicrobial resistance and biofilm-associated infections demands multifunctional nanomaterials with improved efficacy and safety. In this study, defect-engineered nickel titanate (NiTiO₃) nanoparticles functionalized with L-Ornithine (NiTiO₃-LO) were synthesized via a co-precipitation approach to enhance antimicrobial performance while maintaining biocompatibility. XRD analysis confirmed phase-pure rhombohedral NiTiO₃ with reduced crystallite size upon functionalization (31.3 ± 2 nm to 26.2 ± 2 nm). XPS and FTIR analyses verified successful LO surface coordination and modulation of oxygen vacancy-related defect states. PL studies revealed defect-mediated green emissions (507-529 nm), indicating stabilized oxygen vacancies after functionalization. NiTiO₃-LO exhibited significantly enhanced antibacterial and antifungal activity, with inhibition zones of 17.9 ± 0.4 mm and 18.9 ± 0.4 mm, respectively. The nanoparticles also demonstrated concentration-dependent antioxidant activity, achieving ~ 63% DPPH scavenging at 100 µg/mL, comparable to Vitamin C (~ 65%). Importantly, zebrafish embryo assays showed no observable developmental toxicity, indicating favourable in vivo biocompatibility. These findings establish NiTiO₃-LO as a defect-modulated, multifunctional nanoplatform integrating antimicrobial, antioxidant, and biocompatible properties for potential biomedical applications.
Indexed as
Identifiers
41945138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.